Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
Phase II study evaluates treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive blood cancer
The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) targets the CD123 antigen, which is overexpressed in BPDCN
PVEK monotherapy demonstrated strong responses, enabling ability to proceed with stem cell transplant for high-risk subgroup of patients with BPDCN
Seventy-five percent of patients...
Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus
Glioblastoma is a deadly brain cancer that suppresses the immune system and doesn’t respond well to available therapies
Researchers engineered...
First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
The novel cell therapy, called RB-1355, appears safe and well tolerated
RB-1355 offers unique advantages, such as being ready in about one week...
Americans prefer to screen for cervical cancer in-clinic vs. at home
More than 60% of American women prefer to get their cervical cancer screening in a clinic versus at home with a self-sampling kit, study finds
Black women are less likely to prefer at-home cervical cancer screening
In May, the FDA approved the first home-based self-sampling device for cervical cancer screening
HOUSTON, FEBRUARY 6, 2026 – American women now have the option of screening for cervical cancer at home, using newly approved...
Study shows strong evidence for effectiveness of metastasis-directed radiation therapy in prostate cancer
Metastasis-directed therapy (MDT) significantly improved progression-free survival and later endpoints
Data indicate statistically significant...